Unaudited NAV for March 2023

Arix Bioscience PLC (ARIX) Unaudited NAV for March 2023 17-Apr-2023 / 07:00 GMT/BST Arix Bioscience plc Unaudited NAV for March 2023 LONDON, 17 April 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited Net Asset Value (“NAV”) of the Company for the date ended 31 March 2023 as follows: Date NAV Breakdown Total NAV NAV per share Listed Portfolio Unlisted Portfolio Cash Other Interests 31 March 2023 (unaudited) £42.9m £66.6m £108.7m £3.1m £221.3m £1.71 [ENDS] Enquiries For more information on Arix, please contact: Arix Bioscience plc [phone] [e-mail] Powerscourt Group Sarah MacLeod, Ibrahim Khalil, Nick Johnson [phone] [e-mail] About Arix Bioscience plc Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

ISIN:	GB00BD045071
Category Code:	MSCL
TIDM:	ARIX
LEI Code:	213800OVT3AHQCXNIX43
OAM Categories:	3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:	237106
EQS News ID:	1608427

End of Announcement	EQS News Service